Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU: "potential serious risk" definition for devices

This article was originally published in Clinica

Executive Summary

The European Commission's Directorate General Enterprise is to publish a list of examples of issues that would not normally be considered as grounds for a "potential serious risk to public health" in the context of Directive 2001/83/EC, the Community code relating to medicinal products for human use. The examples promise to be useful to manufacturers of combination products and products on the drug/device borderline area, as well as of general background use to all manufacturers of medtech products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel